Search

everythinglearnresearchcommunity

for

Search:↓

A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.

High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.

A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Bimekizumab effectively treats scalp cellulitis and improves quality of life.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Dupilumab can cause unexpected scalp issues, so early symptom recognition is important to avoid hair loss.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Upadacitinib improved multiple immune-related conditions in one patient.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

Dupilumab can both improve and worsen alopecia areata, with higher IgE levels linked to better outcomes.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Dupilumab for skin problems might reactivate hair loss in some patients.

Dutasteride reduces DHT more effectively than finasteride.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Deucravacitinib helped a man regrow hair significantly.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

The drug combination was safe and showed promise in treating advanced tumors.

The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Tocilizumab might be an effective treatment for COVID-19.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.